Johnson & Johnson reports strong quarter

Note: This section contains information in English only.
Source: Dukascopy Bank SA
In the second quarter of 2025, Johnson & Johnson reported strong results, with sales of $23.7 billion, up 5.8% from the same period last year. Operational sales, which exclude the impact of currency changes, grew by 4.6%, and adjusted operational sales rose 3.0%. The company earned $2.29 per share (GAAP), up 18.7%, while adjusted earnings per share were $2.77, slightly down from last year. Net earnings rose to $5.54 billion, while adjusted net earnings dipped slightly to $6.70 billion. Free cash flow for the year so far was about $6.2 billion, down from $7.5 billion last year.



Sales in the U.S. rose 7.8% to $13.5 billion, while international sales increased 3.2% to $10.2 billion. Johnson & Johnson also made progress in its pipeline, with key updates including FDA approval of IMAAVY for a rare muscle disease, priority review for a new bladder cancer drug (TAR-200), and promising data from the cancer treatment CARVYKTI. The company is also continuing development of its robotic surgery system, OTTAVA. Thanks to this strong performance, the company raised its full-year 2025 forecast. It now expects sales to grow 5.4% and raised its full-year earnings forecast to $10.85 per share (GAAP) and $10.68 adjusted. CEO Joaquin Duato said the results show the strength of J&J's mix of businesses and innovation pipeline, and he expects even stronger growth in the second half of the year.
Back to articles

Actual Topics

Tue, 22 Jul 2025 07:50:05 GMT

Ryanair quarter earnings

Ryanair reported a strong Q1 2025 profit of €820 million, up from €360 million a year earlier, driven by 21% higher fares and 4% traffic growth to 58 million passengers. Total revenue rose 20% to €4.34 billion, while operating costs increased just 5%, helped by strong fuel hedging. The airline maintains a solid balance sheet with €4.4 billion in cash

Tue, 15 Jul 2025 10:50:06 GMT

Blackrock quarter earnings

BlackRock reported Q2 2025 earnings with diluted EPS of $10.19, or $12.05 on an adjusted basis. Revenue rose 13% from a year ago, helped by strong markets, fee growth, and higher tech and subscription income. GAAP operating income fell 4% due to acquisition-related costs, but adjusted operating income rose 12%. The company had $68 billion in net inflows for the

Subscribe to "Fundamental Analysis" feed

Abonnieren
Um mehr über die Forex/CFD Handelsplattform von Dukascopy Bank SA, sowie über den SWFX und weitere handelsbezogene Informationen zu erfahren,
rufen Sie uns bitte an oder hinterlassen Sie eine Rückrufanfrage.
Für weitere Informationen über eine mögliche Zusammenarbeit,
bitte rufen Sie uns an oder fordern Sie einen Rückruf an.
Um mehr über die Dukascopy Bank Binären Optionen zu lernen /Forex Handelsplattform, SWFX und andere Handelsbezogenen Informationen,
bitte rufen Sie uns an oder fordern Sie einen Rückruf an.
Um mehr über die Forex/CFD Handelsplattform von Dukascopy Bank SA, sowie über den SWFX und weitere Handelsbezogenen Informationen zu erfahren,
rufen Sie uns bitte an oder hinterlassen Sie eine Rückrufanfrage.
Um mehr über Krypto Handel/CFD/ Forex Handelsplattform, SWFX und andere Handelsbezogenen Informationen zu erfahren,
bitte rufen Sie uns an oder fordern Sie einen Rückruf an.
Um mehr über Business Introducer und andere Handelsbezogenen Informationen zu erfahren,
bitte rufen Sie uns an oder fordern Sie einen Rückruf an.
Für weitere Informationen über eine mögliche Zusammenarbeit,
rufen Sie uns bitte an oder bitten Sie um einen Rückruf.